ReviewJournal of hepatocellular carcinoma2021
Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide.
Review in Journal of hepatocellular carcinoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Quantitative Hepatobiliary Phase Signal Analysis of HCC Nodules on Gd-EOB-DTPA-Enhanced MRI: A Potential Imaging Biomarker Associated with Disease Control After Conventional Transarterial Chemoembolization (cTACE).Journal of clinical medicine · 2026Article
- Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers · 2026Review
- Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.Frontiers in oncology · 2026Article
- Tumor calcification and sustained complete response after chemoembolization in hepatocellular carcinoma: Two case reports and review of literature.World journal of gastrointestinal oncology · 2025Article
- Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization.Diagnostics (Basel, Switzerland) · 2025Review
- Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.Journal of clinical laboratory analysis · 2025Article
- Integrating CT Radiomics and Clinical Features to Optimize TACE Technique Decision-Making in Hepatocellular Carcinoma.Cancers · 2025Article
- Early release of circulating tumor cells after transarterial chemoembolization hinders therapeutic response in patients with hepatocellular carcinoma.Journal of translational medicine · 2025Article
- Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2025Article
- The TBS-PALB-NLR Triad: A Novel Preoperative Prognostic System Guiding Therapeutic Decision-Making in Unresectable HCC Treated with Transarterial Chemoembolization.Journal of hepatocellular carcinoma · 2025Article
- Sultan's Score: A Novel Predictive Score to Predict Complete Response Following Drug-Eluting Bead Chemoembolization.Cureus · 2025Article
- AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study.JHEP reports : innovation in hepatology · 2024Article
- Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment.Scientific reports · 2024Article
- Review
- Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.Journal of cancer research and clinical oncology · 2024Article
- Oncolytic mineralized bacteria as potent locally administered immunotherapeutics.Nature biomedical engineering · 2024Article
- Article
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.Journal of hepatocellular carcinoma · 2024Article
- Mapping research trends of transarterial chemoembolization for hepatocellular carcinoma from 2012 to 2021: A bibliometric analysis.World journal of methodology · 2023Article
- Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of hepatocellular carcinoma (HCC) depends on the stage of disease. In the Western Hemisphere, the Barcelona Clinic Liver Cancer classification (BCLC) is the preferred staging system. Approximately one-third of patients initially present with intermediate-stage disease. For these patients, transarterial chemoembolization (TACE) is the treatment of choice. However, the intermediate-stage comprises a heterogeneous subgroup of patients with considerable differences in tumor burden and liver function. In addition, differences in individual factors that are not captured by the BCLC framework, such as the tumor growth pattern, degree of hypervascularity, and vascular supply, complicate further evaluation of these patients. Due to these differences, not all patients benefit equally from TACE. Several tools and scoring systems have been devised to provide decision-making support. All of these have shown promising initial results but failed external evaluation and have not been translated to the clinic. Nevertheless, criteria for objectifying treatment decisions in daily clinical practice are needed in all stages of disease. Therefore, this review provides a concise practical step-by-step guide on current strategies for patient selection and decision-making, with a focus on TACE, to critically evaluate the existing decision-support tools and provide a summary of the latest updates in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.